EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
EQS-News: MorphoSys AG
/ Key word(s): Conference
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08.01.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Media Release
Planegg/Munich, Germany, January 8, 2024
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company’s Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also be in attendance and available to address questions.
A live webcast of the presentation can be accessed on the Investors section of MorphoSys’ website at https://www.morphosys.com/en/investors. An archived version of the webcast will be available on the company’s website following the presentation.
About MorphoSys
At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn.
For more information, please contact:
Media Contacts:
Thomas Biegi
Senior Vice President, Corporate Affairs
Tel: +49 (0)151 / 74612318
[email protected] |
Investor Contact:
Dr. Julia Neugebauer
Vice President, Global Investor Relations
Tel: +49 (0)89 / 899 27 179
[email protected] |
Eamonn Nolan
Director, Corporate Communications & Investor Relations
Tel: +1 617-548-9271
[email protected] |
|
08.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
MorphoSys AG |
|
Semmelweisstr. 7 |
|
82152 Planegg |
|
Germany |
| Phone: |
+49 (0)89 899 27-0 |
| Fax: |
+49 (0)89 899 27-222 |
| E-mail: |
[email protected] |
| Internet: |
www.morphosys.com |
| ISIN: |
DE0006632003 |
| WKN: |
663200 |
| Indices: |
SDAX, TecDAX |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
| EQS News ID: |
1809537 |
| |
| End of News |
EQS News Service |
1809537 08.01.2024 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
66,79 |
76,44 |
71,76 |
327,69 |
179,61 |
278,27 |
238,28 |
| EBITDA1,2 |
-63,58 |
-55,36 |
-101,67 |
52,08 |
-262,34 |
-202,37 |
-219,67 |
| EBITDA-Marge3 |
-95,19 |
-72,42 |
-141,68 |
15,89 |
-146,06 |
-72,72 |
|
| EBIT1,4 |
-67,61 |
-59,11 |
-107,92 |
27,36 |
-508,34 |
-220,71 |
-252,48 |
| EBIT-Marge5 |
-101,23 |
-77,33 |
-150,39 |
8,35 |
-283,02 |
-79,32 |
-105,96 |
| Jahresüberschuss1 |
-69,83 |
-56,17 |
-103,01 |
97,89 |
-514,46 |
-151,06 |
-189,73 |
| Netto-Marge6 |
-104,55 |
-73,48 |
-143,55 |
29,87 |
-286,43 |
-54,29 |
-79,63 |
| Cashflow1,7 |
-38,45 |
-33,27 |
-80,14 |
35,27 |
-481,45 |
-366,71 |
-295,84 |
| Ergebnis je Aktie8 |
-2,41 |
-1,78 |
-3,26 |
2,97 |
-15,40 |
-4,42 |
-5,53 |
| Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| MorphoSys |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 663200 |
67,850 |
Halten |
2.556,22 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 0,00 |
31,59 |
0,00 |
-19,25 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 52,12 |
- |
10,73 |
-19,35 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 0,00 |
0,00 |
0,00 |
17.05.2023 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 29.04.2024 |
07.08.2024 |
10.10.2024 |
14.03.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| 3,94% |
70,39% |
99,56% |
255,79% |
|
|
MorphoSys AG DE0006632003